BLTE · Insider Trading
Belite Bio, Inc American Depositary Shares
Every open-market purchase and sale reported by BLTE officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-30 | Yu-Hsin Lin | Chief Executive Officer | J | +5,000 | — |
| 2026-10-30 | Wan-Shan Chen | Director | X | +13,796 | +$6.05K |
| 2026-10-30 | Hao-Yuan Chuang | Chief Financial Officer | J | +5,000 | — |
| 2026-10-05 | Hendrik Peter Scholl | Chief Medical Officer | Sell | −500 | −$82.66K |
| 2026-09-09 | Hao-Yuan Chuang | Chief Financial Officer | Sell | −67,395 | −$12.80M |
| 2026-09-09 | Yu-Hsin Lin | Chief Executive Officer | Sell | −100,435 | −$19.08M |
| 2026-08-14 | Hao-Yuan Chuang | Chief Financial Officer | Sell | −367 | −$66.19K |
| 2026-08-14 | Yu-Hsin Lin | Chief Executive Officer | Sell | −365 | −$65.83K |
| 2026-06-22 | Hendrik Peter Scholl | Chief Medical Officer | Sell | −10,000 | −$1.45M |
| 2026-06-17 | Hendrik Peter Scholl | Chief Medical Officer | Sell | −10,000 | −$1.41M |
| 2026-05-08 | Nathan L. Mata | Chief Scientific Officer | Sell | −666 | −$102.04K |
| 2026-05-07 | Nathan L. Mata | Chief Scientific Officer | Sell | −1,000 | −$153.84K |
| 2026-05-06 | Nathan L. Mata | Chief Scientific Officer | Sell | −1,000 | −$155.50K |
| 2026-05-05 | Nathan L. Mata | Chief Scientific Officer | Sell | −1,000 | −$155.64K |
| 2026-05-04 | Nathan L. Mata | Chief Scientific Officer | Sell | −1,000 | −$155.78K |
| 2026-05-01 | Nathan L. Mata | Chief Scientific Officer | Sell | −1,000 | −$156.97K |
| 2026-04-29 | Nathan L. Mata | Chief Scientific Officer | Sell | −1,000 | −$159.16K |
| 2026-04-28 | Nathan L. Mata | Chief Scientific Officer | Sell | −1,000 | −$162.64K |
| 2026-04-27 | Nathan L. Mata | Chief Scientific Officer | Sell | −1,000 | −$159.56K |
| 2026-04-24 | Nathan L. Mata | Chief Scientific Officer | Sell | −1,000 | −$166.28K |
| 2026-04-23 | Yu-Hsin Lin | Chief Executive Officer | J | +10,000 | — |
| 2026-04-23 | Hendrik Peter Scholl | Chief Medical Officer | J | +10,000 deriv. | — |
| 2026-04-23 | Hao-Yuan Chuang | Chief Financial Officer | J | +10,000 | — |
| 2026-04-23 | Nathan L. Mata | Chief Scientific Officer | Sell | −1,000 | −$170.38K |
| 2026-04-22 | Nathan L. Mata | Chief Scientific Officer | Sell | −1,000 | −$166.00K |
| 2026-04-21 | Nathan L. Mata | Chief Scientific Officer | Sell | −1,000 | −$163.59K |
| 2026-04-20 | Nathan L. Mata | Chief Scientific Officer | Sell | −1,000 | −$161.63K |
| 2026-04-20 | Nathan L. Mata | Chief Scientific Officer | Sell | −1,000 | −$160.38K |
| 2026-04-16 | Nathan L. Mata | Chief Scientific Officer | Sell | −1,000 | −$168.30K |
| 2026-04-13 | Wan-Shan Chen | Director | Sell | −1,100 | −$198.47K |
| 2026-04-13 | Hao-Yuan Chuang | Chief Financial Officer | Sell | −6,200 | −$1.13M |
| 2026-04-13 | Yu-Hsin Lin | Chief Executive Officer | Sell | −9,200 | −$1.67M |
| 2026-04-02 | Nathan L. Mata | Chief Scientific Officer | A | +144,868 deriv. | — |
| 2026-04-02 | Wan-Shan Chen | Director | A | +13,796 deriv. | — |
| 2026-04-02 | Hao-Yuan Chuang | Chief Financial Officer | A | +144,868 deriv. | — |
| 2026-04-02 | Yu-Hsin Lin | Chief Executive Officer | A | +206,954 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Hao-Yuan Chuang | Chief Financial Officer | 210,264 | $32.11M |
| Yu-Hsin Lin | Chief Executive Officer | 187,949 | $28.70M |
| Wan-Shan Chen | Director | 37,259 | $5.69M |
| Hendrik Peter Scholl | Chief Medical Officer | 14,500 | $2.21M |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the BLTE quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.